期刊： CLINICAL DRUG INVESTIGATION, 2021; 41 (6)
Background and Objective Trastuzumab emtansine (T-DM1) is the standard second-line option for the treatment of patients with human epidermal growth fa......
期刊： CLINICAL DRUG INVESTIGATION, 2020; 40 (11)
Sodium-glucose cotransporter inhibitors are a new class of oral antihyperglycemic drugs that have been approved for the treatment of patients with typ......
期刊： CLINICAL DRUG INVESTIGATION, 2020; 40 (1)
Background and ObjectiveBecause of the narrow therapeutic window and huge inter-individual variation, the individual precision on anticoagulant therap......
期刊： CLINICAL DRUG INVESTIGATION, 2020; 40 (1)
BackgroundA CYP2D6 gene polymorphism is related to the effect of tamoxifen treatment in patient with estrogen-receptor positive (ER) positive breast c......
期刊： CLINICAL DRUG INVESTIGATION, 2020; 40 (2)
BackgroundCrizotinib, ceritinib, and alectinib improved survival in patients with anaplastic lymphoma kinase (ALK) arrangement non-small-cell lung can......
期刊： CLINICAL DRUG INVESTIGATION, 2020; 40 (2)
BackgroundVenous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is an important cause of post-surgery m......
期刊： CLINICAL DRUG INVESTIGATION, 2020; 40 (6)
Background The predominance of onychomycosis has been increasing recently. New medications and treatment modalities are being researched for better sa......
期刊： CLINICAL DRUG INVESTIGATION, 2020; 40 (6)
Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in Wuhan, China and spread rapidly. Recent studies have found that & ......
期刊： CLINICAL DRUG INVESTIGATION, 2020; 40 (6)
Background and Objective Bentysrepinine (Y101), a derivative of repensine (a compound isolated from Dichondra repens Forst), is a novel phenylalanine ......
期刊： CLINICAL DRUG INVESTIGATION, 0; ()
Background and Objectives Oxycodone tamper resistant (OTR) is a new extended-release abuse-deterrent formulation providing improvements in the tamper ......
期刊： CLINICAL DRUG INVESTIGATION, 0; ()
Background and Objective The economic assessment of immuno-oncology agents in Chinese patients is limited despite a need for new therapies. Nivolumab ......
期刊： CLINICAL DRUG INVESTIGATION, 2019; 39 (1)
Background and ObjectiveTylerdipine hydrochloride (KBP-5660) is a novel L/T-type dual calcium channel blocker developed for thetreatment of hypertensi......
